Overview

BL Infusion Trial: Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia

Status:
Not yet recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

The study plans to randomize a total of 240 patients infected with Gram-negative bacterial pneumonia to receive beta-lactam (meropenem, cefepime, or piperacillin/tazobactam) continuous or intermittent infusion and collect baseline and regular follow-up respiratory cultures to assess the development of new resistance. The investigators will measure beta-lactam concentration to assess the impact of drug exposure on the bacterial resistance.

Phase:

Phase 4

Details

Lead Sponsor:

University of Florida

Collaborator:

Food and Drug Administration (FDA)

Treatments:

Cefepime
Meropenem
Piperacillin
Piperacillin, Tazobactam Drug Combination
Tazobactam